Table 4.

Clinicopathologic features of papillary thyroid carcinoma with and without the BRAF V600E mutation, RAS mutation, RET rearrangements

	BRAF mutation, No. (%)			RAS mutation, No. (%)			RET rearrangements
Characteristics	Negative	Positive	P value	Negative	Positive	P value	Negative	Positive	P value
Age at diagnosis, y
≤45	24	15	0.011	38	1	1.00	30	9	0.009
>45	7	18		24	1		25	0
Sex
Female	22	20	0.438	40	2	0.542	35	7	0.707
Male	9	13		22	0		20	2
Tumor size, cm
≤1	21	24	0.786	43	5	1.000	39	6	1.000
>1	10	9		19	0		16	3
Histologic subtype
Classic type	19	19	0.803	36	2	0.510	31	7	0.291
Follicular variant or other	12	14		26	0		24	2
Multifocality
Absent	16	14	0.462	29	1	1.000	24	6	0.285
Present	15	19		33	1		31	3
Extrathyroidal extension
Absent	13	6	0.013	19	0	1.000	18	1	0.260
Present	18	27		43	2		37	8
Lymph node involvement
Absent	19	15	0.222	33	1	1.000	32	2	0.071
Present	12	18		29	1		23	7
Infiltration
Absent	28	25	0.186	52	1	0.316	47	6	0.177
Present	3	8		10	1		8	3
Distant metastasis
Absent	28	29	1.000	55	2	1.000	50	7	0.253
Present	3	4		7	0		5	2
TNM stagea
I-II	23	26	0.665	47	2	1.000	42	7	1.000
III-IV	8	7		15	0		13	2
Accompanying nodular goiter
Absent	25	27	0.904	51	1	0.342	44	8	0.679
Present	6	6		11	1		11	1
Accompanying Hashimoto
Absent	22	27	0.382	47	2	1.000	43	6	0.427
Present	9	6		15	0		12	3

^aBased on criteria established by American Joint Cancer Committee-Union.

Internationale Contre le Cancer, Seventh Edition, Staging System.